Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa, Safety Study of the Active Implantable(Radiological) Medical Device 32P BioSilicon, Administered Intratumourally to Patients With Advanced, Unresectable Pancreatic Cancer, in Addition to Standard IV Gemcitabine Chemotherapy

NCT00346281 is registered in ClinicalTrials.gov with pSiMedica Limited as lead sponsor.

NCT NCT00346281
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00346281 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa, Safety Study of the Active Implantable(Radiological) Medical Device 32P BioSilicon, Administered Intratumourally to Patients With Advanced, Unresectable Pancreatic Cancer, in Addition to Standard IV Gemcitabine Chemotherapy
Lead sponsor
pSiMedica Limited
Phase
Phase 2
Overall status
Unknown status
Start date
June 30, 2006
Completion date
June 30, 2008
Enrollment
15
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer